The Paul-Ehrlich-Institut (PEI) has indicated that those medicinal products Avastin and Herceptin which are of French origin be classified as illegal with a high probability, if exported from France and marketed/sold on other European markets.
In France, Avastin and Herceptin are delivered by the marketing authorisation holder directly to hospitals and clinics.
The French medicines authority (ANSM) confirmed to the European Medicines Agency (EMA) that hospitals and clinics are not entitled to export medicines from France.
The Paul-Ehrlich-Institut therefore recommends that it should be clarified whether or not the export is legal for the entire supply chain of these medicines if these were/shall be marketed or distributed on the German market.
Updated: 19.12.2018
